Female Viagra

Product Description

Female Viagra (sildenafil) is an oral drug formulated for women who have difficulties experiencing sexual excitement and reaching orgasm. Female Viagra in New Zealand is a legally produced drug approved by FDA. Female Viagra is an analogue of the classical Viagra for men with the same active ingredient, sildenafil, promoting blood circulation in the genital area and thus ensuring sexual excitement.

Common Use

Female Viagra is recommended for various problems of the sexual sphere:

• Vaginal dryness
• Sexual coldness until frigidity;
• Anorgasmia;
• Low sensitivity of the genitals;
• Painful intercourse, including that of psychological genesis.

Contraindications

• Hypersensitivity to the active substance or to any of the excipients.
• Given the knowledge of its mode of action at the level of nitric oxide / cyclic guanosine monophosphate (cGMP), sildenafil in the composition of Female Viagra has been shown to potentiate the hypotensive effects of nitrates by sildenafil and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form whatsoever is against inappropriate.
• Drugs used in the treatment of sexual disorders, including sildenafil, should not be used in men for whom sexual activity is inadvisable (eg patients with severe cardiovascular disorders such as unstable angina. or severe heart failure).

Precautions

Female Viagra should not be taken with meals high on fat and alcohol, as the former may slow down or totally inhibit its action, and the latter can potentiate the risk of development of the side effects. Do not take more than one dose of Female Viagra per day. Consult your GP and gynaecologist before you buy Female Viagra in New Zealand. Female Viagra use is prohibited in pregnant women as sildenafil effects on foetus has not been studied yet.

Possible Side Effects

The safety profile of Female Viagra is based on 8691 patients who received the recommended doses in 67 placebo-controlled clinical trials. The adverse events most frequently reported during clinical trials among sildenafil treated patients were headache, flushing, dyspepsia, blurred vision, nasal congestion, dizziness and impaired color vision.

Adverse reactions reported during post-marketing surveillance measures an estimated 9 years period. The frequencies of these effects cannot be reliably determined because the side effects are not regularly reported and included in the database of tolerance.

In clinical studies, Female Viagra tolerability was good. In placebo-controlled clinical trials, the rates of discontinuation due to adverse events were low and comparable to that of placebo. Adverse events were generally transient and mild or moderate in intensity. In clinical studies, with individual selection of doses, more frequent were the following adverse events, whose connection with the administration of the drug was possible, probable or unknown: Cardiovascular – headache, flushing, dizziness, digestion – dyspepsia; breathing – stuffy nose senses – vision changes (mild and transient, mostly change the color of objects, as well as increased perception of light and blurred vision). When using the drug in doses than recommended, adverse events were similar to the above, but usually occurred more frequently.